Cannabis is the most used illicit drug in the world. Global trends of decriminalization and legali- zation of cannabis lead to various forms of cannabis use and bring great concerns over adverse events, partic- ularly in the cardiovascular (CV) system. To date, the association between cannabis and adverse CV events is still controversial. We aim to conduct a systematic review and meta-analysis to assess the adverse CV events from cannabis use.
The last two decades have seen a dramatic shift in cannabis legislation around the world. Cannabis products are now widely available and commercial production and use of phytocannabinoid products is rapidly growing. However, this growth is outpacing the research needed to elucidate the therapeutic efficacy of the myriad of chemical compounds found primarily in the flower of the female cannabis plant. This lack of research and corresponding regulation has resulted in processing methods, products, and terminology that are variable and confusing for consumers.
Existing reviews exploring cannabis effectiveness have numerous limitations including narrow search strategies. We systematically explored cannabis effects on PTSD symptoms, quality of life (QOL), and return to work (RTW). We also investigated harm outcomes such as adverse effects and dropouts due to adverse effects, inefficacy, and all-cause dropout rates.